Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31231172 | 0.94 | HPGD (0.47) | USP2SMN1; SMN2FFAR3HPGDEPHX2 | |
| SCHEMBL14709673 | 0.94 | HPGD (0.47) | USP2SMN1; SMN2FFAR3HPGDEPHX2 | |
| SCHEMBL10068313 | 0.91 | HPGD (0.51) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL31693670 | 0.90 | USP2 (0.46) | USP2SMN1; SMN2FFAR3HPGDEPHX2 | |
| SCHEMBL12373947 | 0.90 | USP2 (0.45) | USP2SMN1; SMN2FFAR3HPGDEPHX2 | |
| SCHEMBL22625915 | 0.90 | HPGD (0.49) | USP2SMN1; SMN2FFAR3HPGDEPHX2 | |
| SCHEMBL17469418 | 0.90 | USP2 (0.45) | USP2SMN1; SMN2FFAR3HPGDEPHX2 | |
| SCHEMBL2285992 | 0.90 | USP2 (0.45) | USP2SMN1; SMN2FFAR3HPGDEPHX2 | |
| SCHEMBL25191312 | 0.87 | HPGD (0.66) | USP2SMN1; SMN2HPGDGPR119RECQL | |
| SCHEMBL13689493 | 0.86 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079868-A | Synthesis method of N-alkoxycarbonyl-4-amino-4-alkylpiperidine | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4714499-A2 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250263405-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | VALO HEALTH, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250230129-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) | 2025-07-17 | — | — | US | disclosed |
| US-6083949-A | FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR | MERCK & CO., INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-6020347-A | 4-substituted-4-piperidine carboxamide derivatives | MERCK & CO., INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999025685-A1 | 4-SUBSTITUTED-4-PIPERIDINE CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0854870-A4 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | disclosed |
| CN-1203590-A | Substituted imidazoles having anti-cancer and cytokine inhibitory activity | MERCK & CO INC (US) | 1998-12-30 | — | — | CN | disclosed |
| EP-0854870-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1998016527-A1 | BENZOXEPINE DERIVATIVES WHICH PROMOTE RELEASE OF GROWTH HORMONE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-23 | — | — | WO | disclosed |
| US-5717100-A | Substituted imidazoles having anti-cancer and cytokine inhibitory activity | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1997012876-A9 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | — | 1997-09-18 | — | — | WO | disclosed |
| WO-1997012876-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | USP2 2291/4885SMN1; SMN2 4785/4885FFAR3 394/4885 |
| US-20250230129-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | ADCYAP1R1, PAICS, AGPS | USP2 2353/4885SMN1; SMN2 948/4885FFAR3 1420/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | USP2 3194/4885SMN1; SMN2 4657/4885FFAR3 685/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | USP2 1115/4885SMN1; SMN2 1443/4885FFAR3 308/4885 |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | MEN1, MLLT1, MSI2 | USP2 3835/4885SMN1; SMN2 2354/4885FFAR3 4339/4885 |
| US-20250263405-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | USP2 692/4885SMN1; SMN2 1998/4885FFAR3 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.